Review of Meningococcal Group B Vaccines

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Feb 11

PMID 20144017

Citations 77

Authors

Dan M Granoff

Affiliations

Soon will be listed here.

Abstract

No broadly effective vaccines are available for prevention of group B meningococcal disease, which accounts for >50% of all cases. The group B capsule is an autoantigen and is not a suitable vaccine target. Outer-membrane vesicle vaccines appear to be safe and effective, but serum bactericidal responses in infants are specific for a porin protein, PorA, which is antigenically variable. To broaden protection, outer-membrane vesicle vaccines have been prepared from >1 strain, from mutants with >1 PorA, or from mutants with genetically detoxified endotoxin and overexpressed desirable antigens, such as factor H binding protein. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with other antigens, are in late-stage clinical development and may be effective against the majority of group B strains. Thus, the prospects have never been better for developing vaccines for prevention of meningococcal disease, including that caused by group B strains.

Citing Articles

Immunogenicity of Outer Membrane Vesicles: Elucidation of Humoral Responses against OMV-Associated Antigens.

Croia L, Sopetto G, Zanella I, Caproni E, Gagliardi A, Tamburini S Membranes (Basel). 2023; 13(11).

PMID: 37999368 PMC: 10673343. DOI: 10.3390/membranes13110882.

Miguelena Chamorro B, De Luca K, Swaminathan G, Longet S, Mundt E, Paul S Clin Microbiol Rev. 2023; 36(3):e0016422.

PMID: 37306571 PMC: 10512794. DOI: 10.1128/cmr.00164-22.

Whole genome sequence analysis of Neisseria meningitidis strains circulating in Kazakhstan, 2017-2018.

Shevtsov A, Aushakhmetova Z, Amirgazin A, Khegay O, Kamalova D, Sanakulova B PLoS One. 2022; 17(12):e0279536.

PMID: 36576937 PMC: 9797059. DOI: 10.1371/journal.pone.0279536.

Bacterial extracellular vesicle applications in cancer immunotherapy.

Suri K, DSouza A, Huang D, Bhavsar A, Amiji M Bioact Mater. 2022; 22:551-566.

PMID: 36382022 PMC: 9637733. DOI: 10.1016/j.bioactmat.2022.10.024.

Outer Membrane Vesicles: An Emerging Vaccine Platform.

Kashyap D, Panda M, Baral B, Varshney N, R S, Bhandari V Vaccines (Basel). 2022; 10(10).

PMID: 36298443 PMC: 9610665. DOI: 10.3390/vaccines10101578.

References

Moe G, Zuno-Mitchell P, Hammond S, Granoff D . Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun. 2002; 70(11):6021-31. PMC: 130404. DOI: 10.1128/IAI.70.11.6021-6031.2002. View

Rappuoli R, Covacci A . Reverse vaccinology and genomics. Science. 2003; 302(5645):602. DOI: 10.1126/science.1092329. View

Finney M, Vaughan T, Taylor S, Hudson M, Pratt C, Wheeler J . Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin. 2007; 4(1):23-30. DOI: 10.4161/hv.4.1.4806. View

Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W . Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun. 2005; 73(7):4070-80. PMC: 1168616. DOI: 10.1128/IAI.73.7.4070-4080.2005. View

Plested J, Harris S, Wright J, Coull P, Makepeace K, Gidney M . Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis. 2003; 187(8):1223-34. DOI: 10.1086/368360. View

Zollinger W, Mandrell R . Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983; 40(1):257-64. PMC: 264843. DOI: 10.1128/iai.40.1.257-264.1983. View

Pace D, Pollard A, Messonier N . Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009; 27 Suppl 2:B30-41. DOI: 10.1016/j.vaccine.2009.05.003. View

Bernardini G, Braconi D, Martelli P, Santucci A . Postgenomics of Neisseria meningitidis for vaccines development. Expert Rev Proteomics. 2007; 4(5):667-77. DOI: 10.1586/14789450.4.5.667. View

Thompson E, Feavers I, Maiden M . Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology (Reading). 2003; 149(Pt 7):1849-1858. DOI: 10.1099/mic.0.26131-0. View

10.

van der Ley P, Steeghs L, Hamstra H, Ten Hove J, Zomer B, van Alphen L . Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001; 69(10):5981-90. PMC: 98725. DOI: 10.1128/IAI.69.10.5981-5990.2001. View

11.

de Kleijn E, de Groot R, Lafeber A, Labadie J, van Limpt C, Visser J . Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J Infect Dis. 2001; 184(1):98-102. DOI: 10.1086/320993. View

12.

Jacobsson S, Thulin Hedberg S, Molling P, Unemo M, Comanducci M, Rappuoli R . Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine. 2009; 27(10):1579-84. DOI: 10.1016/j.vaccine.2008.12.052. View

13.

De Groot A, Rappuoli R . Genome-derived vaccines. Expert Rev Vaccines. 2004; 3(1):59-76. DOI: 10.1586/14760584.3.1.59. View

14.

Hoiby E, Bjune G, Froholm L, Eng J, Halstensen A, Rosenqvist E . The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann. 1991; 14(2):107-21; discussion 121-3. View

15.

Plested J, Granoff D . Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol. 2008; 15(5):799-804. PMC: 2394837. DOI: 10.1128/CVI.00036-08. View

16.

OHallahan J, Lennon D, Oster P, Lane R, Reid S, Mulholland K . From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine. 2005; 23(17-18):2197-201. DOI: 10.1016/j.vaccine.2005.01.061. View

17.

Welsch J, Ram S, Koeberling O, Granoff D . Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis. 2008; 197(7):1053-61. DOI: 10.1086/528994. View

18.

Martin S, Borrow R, van der Ley P, Dawson M, Fox A, Cartwright K . Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine. 2000; 18(23):2476-81. DOI: 10.1016/s0264-410x(00)00047-5. View

19.

de Kleijn E, de Groot R, Labadie J, Lafeber A, van den Dobbelsteen G, van Alphen L . Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine. 2000; 18(15):1456-66. DOI: 10.1016/s0264-410x(99)00423-5. View

20.

Koeberling O, Seubert A, Granoff D . Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis. 2008; 198(2):262-70. PMC: 3755350. DOI: 10.1086/589308. View